Abstract: The present disclosure provides various insights relating to treatment of viral infection with soluble ACE2 variants, specifically including soluble human ACE2 (hACE2) variants. For example, the present disclosure teaches that decoy activity, which may intercept virus-receptor interactions, and ACE2 enzymatic activity can provide separate contributions to therapeutic efficacy; among other things, the present disclosure provides particular therapeutic regimens (e.g., relating to treatment of particular patient populations and/or to dosing regimens, combination therapies, etc.) for certain soluble ACE2 variants. Still further, the present disclosure provides certain particular ACE2 variants and methods of making and/or using them, including in accordance with particular therapeutic regimens.
Abstract: Compositions and methods for darkening hair of intact skin are presented. Such compositions include defensins in concentrations that are below those that exhibit antimicrobial activity, and can be in the form of a topically applied formulation. Various formulations for such compositions, which can include various pharmaceutically acceptable stabilizers, emollients, and fragrances, are provided.
Abstract: The present invention relates to conjugation-competent albumins and albumin-related polypeptides, and their conjugates with at least one moiety, and to polynucleotides encoding them.
Type:
Grant
Filed:
March 28, 2022
Date of Patent:
October 15, 2024
Assignee:
SARTORIUS ALBUMEDIX LIMITED
Inventors:
Karen Ann Delahay, Christopher John Arthur Finnis, Karl Michael Nicholls
Abstract: In various aspects, the present disclosure pertains to sorbents for isolating at least one target protein from a liquid sample, the sorbents comprising a solid support comprising attached at least one attached high affinity reagent with an affinity for the at least one target protein. Other aspects of the present disclosure include kit that contain such sorbents and methods of treating samples using the same.
Abstract: Provided herein are methods shifting the isoelectric profile of a recombinant protein product and the use of such methods in the manufacture of recombinant protein products. Also provided are recombinant protein products produced by such methods.
Type:
Grant
Filed:
June 11, 2020
Date of Patent:
June 25, 2024
Assignee:
Alexion Pharmaceuticals, Inc.
Inventors:
Hunter F. Malanson, Pratik Jaluria, Rachael Alford
Abstract: The present invention relates to a highly contracted artificial fibroin fiber including a modified fibroin, in which a contraction percentage defined by the following equation exceeds 7%.
Abstract: A coat protein of Junonia coenia densovirus (JcDNV) is used to deliver attached peptide insect toxin across the gut epithelium of a fall armyworm, Spodoptera frugiperda. A fusion protein comprising VP4 attached to an insect toxin via a peptide linker is developed. A composition comprising a JcDNV coat protein attached to an insect toxin via a peptide linker can be used for insect pest control.
Type:
Grant
Filed:
September 9, 2021
Date of Patent:
June 25, 2024
Assignees:
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED, Iowa State University Research Foundation, Inc.
Abstract: The present application provides engineered polypeptides having imine or oxime reductase activity, polynucleotides encoding the engineered polypeptides, host cells capable of expressing the engineered polypeptides, and methods of using these engineered polypeptides with a range of ketone and amine substrate compounds to prepare secondary and tertiary amine product compounds.
Type:
Grant
Filed:
May 26, 2021
Date of Patent:
May 21, 2024
Assignee:
Codexis, Inc.
Inventors:
Margie Tabuga Borra-Garske, Oscar Alvizo, Melissa Ann Mayo, Stephan Jenne, Auric Anthony Sowell-Kantz, Carmela Molinaro
Abstract: The present invention provides engineered penicillin G acylase (PGA) enzymes having improved properties, polynucleotides encoding such enzymes, compositions including the enzymes, and methods of using the enzymes.
Type:
Grant
Filed:
November 30, 2021
Date of Patent:
April 23, 2024
Assignee:
Codexis, Inc.
Inventors:
Jovana Nazor, Vesna Mitchell, David Elgart, Katrina W. Lexa, Nikki Dellas, Robert Kevin Orr, Oscar Alvizo, Ravi David Garcia, Judy Victoria Antonio Viduya, Courtney Dianne Moffett
Abstract: The present invention provides a recombinant exosome and uses thereof. More particularly, the present invention provides a recombinant exosome wherein a phagocytosis promoting protein is presented on the surface of the exosome.
Type:
Grant
Filed:
April 3, 2022
Date of Patent:
April 9, 2024
Assignee:
SHIFTBIO
Inventors:
Eun-ee Koh, Eun Jung Lee, Yoo Soo Yang, In-San Kim
Abstract: The present invention provides for a mechanism to reduce glycerol production and increase nitrogen utilization and ethanol production of recombinant microorganisms. One aspect of this invention relates to strains of S. cerevisiae with reduced glycerol productivity that get a kinetic benefit from higher nitrogen concentration without sacrificing ethanol yield. A second aspect of the invention relates to metabolic modifications resulting in altered transport and/or intracellular metabolism of nitrogen sources present in corn mash.
Abstract: The invention provides a process for preparing sphingolipids, compositions comprising sphingolipids and further components, and for the use of the compositions.
Type:
Grant
Filed:
October 8, 2021
Date of Patent:
March 26, 2024
Assignee:
Evonik Operations GmbH
Inventors:
Marrit Friederike Eckstein, Monica Desiree van Logchem, Hans Henning Wenk, Annika Schrader, Ursula Maczkiewitz, Claudia Hierath, Sunay Karacocuk, Andreas Seifert
Abstract: The present invention relates to a method for producing fucosylated oligosaccharides by using a recombinant prokaryotic host cell that is cultivated on a gluconeogenic substrate, as well as to the host cell and its use. The host cell is genetically modified in that the activity of a fructose-6-phosphate converting enzyme is abolished or lowered, and the transport of the produced fucosylated oligosaccharide through the cell membrane is facilitated by an exogenous transport protein.
Type:
Grant
Filed:
October 24, 2017
Date of Patent:
February 13, 2024
Assignee:
Chr Hansen HMO GmbH
Inventors:
Stefan Jennewein, Dirk Wartenberg, Katja Parschat
Abstract: The present invention relates to new peptidic compounds, more specifically to micropeptides derived from lncRNAs implicated in cancer and cellular plasticity. It also relates to the use of the said micropeptides in the treatment of proliferative diseases, more specifically in the treatment of cancer.
Type:
Grant
Filed:
March 15, 2019
Date of Patent:
January 2, 2024
Assignee:
Fundació Privada Institut d'Investigació Oncològica de Vall Hebron
Inventors:
Maria Abad Méndez, Olga Boix Sánchez, Emanuela Greco, Iñaki Merino Valverde
Abstract: This invention relates to elastomeric protein and elastomeric protein production. In particular, the invention is directed to elastomeric protein sequences, including methods and compositions for production of elastomeric protein sequences, such as expression constructs, and host cells, and including compositions generated from the elastomeric protein sequences.
Type:
Grant
Filed:
March 31, 2021
Date of Patent:
January 2, 2024
Assignee:
BOLT THREADS, INC.
Inventors:
Joshua Kittleson, Michael Lee, David N. Breslauer, Daniel M. Widmaier
Abstract: Disclosed herein are methods, compositions and kits for the synthesis of proteins which comprises unnatural amino acids that utilize a mutant tRNA.
Type:
Grant
Filed:
March 9, 2021
Date of Patent:
December 5, 2023
Assignees:
THE SCRIPPS RESEARCH INSTITUTE, SYNTHORX, INC.
Inventors:
Jerod Ptacin, Carolina Caffaro, Hans Aerni, Yorke Zhang, Emil C. Fischer, Aaron W. Feldman, Vivian T. Dien, Floyd E. Romesberg
Abstract: A composition and method for preventing or reducing the incidence of a transient ischemic attack in a subject at risk for developing a stroke comprises orally administering to the subject a prophylactically effective amount of a pharmaceutical composition comprising an ASIC1a inhibitor capable of penetrating the blood-brain barrier. Preferred ASIC1a inhibitors for use in the disclosed methods include amiloride and amiloride analogs.
Abstract: Disclosed is a method for producing an alkaline phosphatase fusion antibody, comprising: culturing a cell comprising an expression vector comprising a gene encoding alkaline phosphatase derived from bovine small intestine or Shewanella bacterium and a gene encoding an antibody in a medium comprising a zinc ion, and acquiring an alkaline phosphatase fusion antibody expressed by the cell.
Abstract: The disclosure provides molecules for use in compositions, medicaments and methods for the treatment or prevention of RSV infections, its symptoms and associated pathologies and potentially infections caused or contributed to by viral pathogens which do not bind or do not primarily bind sialic acid containing receptors during pathogenesis. Specifically, the disclosure is based on the finding that molecules with affinity for (or an ability to bind to) sialic acid (and in particular sialoglycoconjugates) on cell surfaces (these including sialic acid containing glycoproteins and cell surface sialic acid receptors), find utility in the treatment and/or prevention of symptoms, infections, diseases and/or conditions associated with respiratory syncytial vims (RSV).
Type:
Grant
Filed:
February 27, 2019
Date of Patent:
November 21, 2023
Assignee:
Pneumagen Ltd
Inventors:
Helen Connaris, Lei Yang, Jane Alexandra Potter